Predictors of therapeutic effect of transarterial chemoembolisation using drug-eluting beads for hepatocellular carcinoma

Y. Asayama, D. Okamoto, Y. Ushijima, A. Nishie, K. Ishigami, Y. Takayama, N. Fujita, H. Honda

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

Aims To identify predictors of a therapeutic effect after transarterial chemoembolisation using drug-eluting beads (DEB-TACE) for hepatocellular carcinoma (HCC). Materials and methods Between January 2015 and July 2015, tumour variables and angiographic data were collected for 25 patients (49 target lesions) after they had undergone the DEB-TACE procedure for HCC. The therapeutic effect was evaluated according to the Response Evaluation Criteria in Cancer of the Liver at follow-up dynamic computed tomography (CT) performed within 1–4 months after the procedure. A p<0.05 was considered significant. Results On a target lesion basis, the objective response (TE3/4) rate was 63.3% (31 of 49). On univariate analysis, larger size (≥2 cm) was a predictor of an objective response (p=0.029). The tumour location of the medial (segment 4) or caudate (segment 1) lobe also indicated a poor therapeutic effect (TE1/2), but not at the level of significance (p=0.051). Multivariate analysis identified tumour size (odds ratio, 8.60; 95% confidence interval, 1.87–62.8) and tumour location (odds ratio, 12.2; 95% confidence interval, 2.12–129.8) as significant factors associated with a therapeutic effect. On a patient basis, 10 of 25 (40%) patients showed complete response/partial response. There were no significant differences between complete response/partial response and stable disease/progressive disease regarding age, gender, tumour markers, history of previous treatment, Child–Pugh class, T-stage, or Barcelona Clinic Liver Cancer Staging. Conclusion A short-term therapeutic effect was associated with tumour size and location on a target lesion basis.

元の言語英語
ページ(範囲)780-785
ページ数6
ジャーナルClinical Radiology
72
発行部数9
DOI
出版物ステータス出版済み - 9 2017

Fingerprint

Therapeutic Uses
Hepatocellular Carcinoma
Pharmaceutical Preparations
Neoplasms
Liver Neoplasms
Odds Ratio
Confidence Intervals
Neoplasm Staging
Tumor Biomarkers
Multivariate Analysis
Tomography

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

これを引用

Predictors of therapeutic effect of transarterial chemoembolisation using drug-eluting beads for hepatocellular carcinoma. / Asayama, Y.; Okamoto, D.; Ushijima, Y.; Nishie, A.; Ishigami, K.; Takayama, Y.; Fujita, N.; Honda, H.

:: Clinical Radiology, 巻 72, 番号 9, 09.2017, p. 780-785.

研究成果: ジャーナルへの寄稿記事

@article{3529e340a1bd4c7d8b82497868daca21,
title = "Predictors of therapeutic effect of transarterial chemoembolisation using drug-eluting beads for hepatocellular carcinoma",
abstract = "Aims To identify predictors of a therapeutic effect after transarterial chemoembolisation using drug-eluting beads (DEB-TACE) for hepatocellular carcinoma (HCC). Materials and methods Between January 2015 and July 2015, tumour variables and angiographic data were collected for 25 patients (49 target lesions) after they had undergone the DEB-TACE procedure for HCC. The therapeutic effect was evaluated according to the Response Evaluation Criteria in Cancer of the Liver at follow-up dynamic computed tomography (CT) performed within 1–4 months after the procedure. A p<0.05 was considered significant. Results On a target lesion basis, the objective response (TE3/4) rate was 63.3{\%} (31 of 49). On univariate analysis, larger size (≥2 cm) was a predictor of an objective response (p=0.029). The tumour location of the medial (segment 4) or caudate (segment 1) lobe also indicated a poor therapeutic effect (TE1/2), but not at the level of significance (p=0.051). Multivariate analysis identified tumour size (odds ratio, 8.60; 95{\%} confidence interval, 1.87–62.8) and tumour location (odds ratio, 12.2; 95{\%} confidence interval, 2.12–129.8) as significant factors associated with a therapeutic effect. On a patient basis, 10 of 25 (40{\%}) patients showed complete response/partial response. There were no significant differences between complete response/partial response and stable disease/progressive disease regarding age, gender, tumour markers, history of previous treatment, Child–Pugh class, T-stage, or Barcelona Clinic Liver Cancer Staging. Conclusion A short-term therapeutic effect was associated with tumour size and location on a target lesion basis.",
author = "Y. Asayama and D. Okamoto and Y. Ushijima and A. Nishie and K. Ishigami and Y. Takayama and N. Fujita and H. Honda",
year = "2017",
month = "9",
doi = "10.1016/j.crad.2017.03.023",
language = "English",
volume = "72",
pages = "780--785",
journal = "Clinical Radiology",
issn = "0009-9260",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Predictors of therapeutic effect of transarterial chemoembolisation using drug-eluting beads for hepatocellular carcinoma

AU - Asayama, Y.

AU - Okamoto, D.

AU - Ushijima, Y.

AU - Nishie, A.

AU - Ishigami, K.

AU - Takayama, Y.

AU - Fujita, N.

AU - Honda, H.

PY - 2017/9

Y1 - 2017/9

N2 - Aims To identify predictors of a therapeutic effect after transarterial chemoembolisation using drug-eluting beads (DEB-TACE) for hepatocellular carcinoma (HCC). Materials and methods Between January 2015 and July 2015, tumour variables and angiographic data were collected for 25 patients (49 target lesions) after they had undergone the DEB-TACE procedure for HCC. The therapeutic effect was evaluated according to the Response Evaluation Criteria in Cancer of the Liver at follow-up dynamic computed tomography (CT) performed within 1–4 months after the procedure. A p<0.05 was considered significant. Results On a target lesion basis, the objective response (TE3/4) rate was 63.3% (31 of 49). On univariate analysis, larger size (≥2 cm) was a predictor of an objective response (p=0.029). The tumour location of the medial (segment 4) or caudate (segment 1) lobe also indicated a poor therapeutic effect (TE1/2), but not at the level of significance (p=0.051). Multivariate analysis identified tumour size (odds ratio, 8.60; 95% confidence interval, 1.87–62.8) and tumour location (odds ratio, 12.2; 95% confidence interval, 2.12–129.8) as significant factors associated with a therapeutic effect. On a patient basis, 10 of 25 (40%) patients showed complete response/partial response. There were no significant differences between complete response/partial response and stable disease/progressive disease regarding age, gender, tumour markers, history of previous treatment, Child–Pugh class, T-stage, or Barcelona Clinic Liver Cancer Staging. Conclusion A short-term therapeutic effect was associated with tumour size and location on a target lesion basis.

AB - Aims To identify predictors of a therapeutic effect after transarterial chemoembolisation using drug-eluting beads (DEB-TACE) for hepatocellular carcinoma (HCC). Materials and methods Between January 2015 and July 2015, tumour variables and angiographic data were collected for 25 patients (49 target lesions) after they had undergone the DEB-TACE procedure for HCC. The therapeutic effect was evaluated according to the Response Evaluation Criteria in Cancer of the Liver at follow-up dynamic computed tomography (CT) performed within 1–4 months after the procedure. A p<0.05 was considered significant. Results On a target lesion basis, the objective response (TE3/4) rate was 63.3% (31 of 49). On univariate analysis, larger size (≥2 cm) was a predictor of an objective response (p=0.029). The tumour location of the medial (segment 4) or caudate (segment 1) lobe also indicated a poor therapeutic effect (TE1/2), but not at the level of significance (p=0.051). Multivariate analysis identified tumour size (odds ratio, 8.60; 95% confidence interval, 1.87–62.8) and tumour location (odds ratio, 12.2; 95% confidence interval, 2.12–129.8) as significant factors associated with a therapeutic effect. On a patient basis, 10 of 25 (40%) patients showed complete response/partial response. There were no significant differences between complete response/partial response and stable disease/progressive disease regarding age, gender, tumour markers, history of previous treatment, Child–Pugh class, T-stage, or Barcelona Clinic Liver Cancer Staging. Conclusion A short-term therapeutic effect was associated with tumour size and location on a target lesion basis.

UR - http://www.scopus.com/inward/record.url?scp=85018639025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018639025&partnerID=8YFLogxK

U2 - 10.1016/j.crad.2017.03.023

DO - 10.1016/j.crad.2017.03.023

M3 - Article

C2 - 28442142

AN - SCOPUS:85018639025

VL - 72

SP - 780

EP - 785

JO - Clinical Radiology

JF - Clinical Radiology

SN - 0009-9260

IS - 9

ER -